NCT03732820 2026-01-29Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZenecaPhase 3 Active not recruiting895 enrolled 19 charts 2 FDA
NCT02987543 2023-10-06Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)AstraZenecaPhase 3 Completed387 enrolled 16 charts 3 FDA